Evidence map›Paper›PMID 37688386›Full record

ReviewStem cells (Dayton, Ohio)2023

Research Models to Mimic Necrotizing Enterocolitis and Inflammatory Bowel Diseases: Focus on Extracellular Vesicles Action.

Miriam Duci, Ludovica De Cesare, Agner Henrique Dorigo Hochuli, Maurizio Muraca, Mara Cananzi, Piergiorgio Gamba, Francesco Fascetti-Leon, Michela Pozzobon

Open access · hybridAbstract readReview
In one paragraph

Review in Stem cells (Dayton, Ohio), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Miriam DuciDepartment of Women's and Children's Health, University of Padova, Padova (PD) - Veneto, Italy.ORCID 0000-0003-1382-3527
Ludovica De CesareStem Cells and Regenerative Medicine Lab, Foundation Institute of Pediatric Research Città della Speranza, Padova (PD) - Veneto, Italy.
Agner Henrique Dorigo HochuliDepartment of Women's and Children's Health, University of Padova, Padova (PD) - Veneto, Italy.ORCID 0000-0003-2900-7655
Maurizio MuracaDepartment of Women's and Children's Health, University of Padova, Padova (PD) - Veneto, Italy.
Mara CananziDepartment of Women's and Children's Health, University of Padova, Padova (PD) - Veneto, Italy.
Piergiorgio GambaDepartment of Women's and Children's Health, University of Padova, Padova (PD) - Veneto, Italy.
Francesco Fascetti-LeonDepartment of Women's and Children's Health, University of Padova, Padova (PD) - Veneto, Italy.
Michela PozzobonDepartment of Women's and Children's Health, University of Padova, Padova (PD) - Veneto, Italy.ORCID 0000-0001-9213-402X
University of Padua · ITCittà della Speranza Foundation · IT

Funding

University of Padova
6 · The paper itself

Abstract

This review focuses on the crucial role of the intestinal epithelium in maintaining intestinal homeostasis and its significance in the pathogenesis of necrotizing enterocolitis (NEC) and inflammatory bowel diseases (IBD). NEC is a devastating neonatal disease, while IBD represents a global healthcare problem with increasing incidence. The breakdown of the intestinal barrier in neonates is considered pivotal in the development and progression of both disorders. This review provides an overview of the current state of in vitro, ex vivo, and animal models to study epithelial injury in NEC and IBD, addressing pertinent questions that engage clinicians and researchers alike. Despite significant advancements in early recognition and aggressive treatment, no single therapy has been conclusively proven effective in reducing the severity of these disorders. Although early interventions have improved clinical outcomes, NEC and IBD continue to impose substantial morbidity, mortality, and economic burdens on affected individuals and society. Consequently, exploring alternative therapeutic options capable of preventing and treating the sequelae of NEC and IBD has become a pressing necessity. In recent decades, extracellular vehicles (EVs) have emerged as a potential solution to modulate the pathogenic mechanism in these multifactorial and complex disorders. Despite the diverse array of proposed models, a comprehensive model to investigate and decelerate the progression of NEC and IBD remains to be established. To bridge the translational gap between preclinical studies and clinical applications, enhancements in the technical development of gut-on-a-chip models and EVs hold considerable promise.

Indexed as

Enterocolitis, NecrotizingExtracellular VesiclesInfant, Newborn, DiseasesInflammatory Bowel DiseasesAnimalsDisease Models, AnimalHumansInfant, Newborn

Identifiers

PMID37688386
PMCPMC10723814
OpenAlexW4386554486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.